Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor

Hepatology

Volumn 59, Issue 1, 2014, Pages 71-77

  Pearlman, Brian L ^a,b,c   Ehleben, Carole ^a  

^a ATLANTA MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; INTERLEUKIN 28B; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; PROLINE; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; DRUG DERIVATIVE; N (3 AMINO 1 (CYCLOBUTYLMETHYL) 2,3 DIOXOPROPYL) 3 (2 ((((1,1 DIMETHYLETHYL)AMINO)CARBONYL)AMINO) 3,3 DIMETHYL 1 OXOBUTYL) 6,6 DIMETHYL 3 AZABICYCLO(3.1.0)HEXAN 2 CARBOXAMIDE;

ADULT; AFRICAN AMERICAN; ANTIVIRAL THERAPY; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS LOAD; ANALOGS AND DERIVATIVES; CONTRAINDICATIONS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; TREATMENT OUTCOME; VIROLOGY; CONTROLLED CLINICAL TRIAL; DRUG CONTRAINDICATION; HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84894816994     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26624     Document Type: Article

References (38)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-1342.
2. WHO | Hepatitis C [Internet]. WHO. [cited 2013 Mar 27]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/
3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
4. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
5. Koh C, Heller T, Haynes-Williams V, Hara K, Zhao X, Feld JJ, et al. Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. Aliment Pharmacol Ther 2013;37:887-894.
6. Swain MG, Lai M-Y, Shiffman ML, Cooksley WGE, Zeuzem S, Dieterich DT, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010;139:1593-1601.
7. Giannini EG, Basso M, Savarino V, Picciotto A. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Aliment Pharmacol Ther 2010;31:502-508.
8. Desmond CP, Roberts SK, Dudley F, Mitchell J, Day C, Nguyen S, et al. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. J Viral Hepat 2006;13:311-315.
9. Zeuzem S, Rodríguez-Torres M, Rajender Reddy K, Marcellin P, Diago M, Craxi A, et al. Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin. J Viral Hepat 2012;19:766-774.
10. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103.
11. Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008;46:78-84.
12. Aziz H, Raza A, Waheed Y, Gill U, Gill ML. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients. Int J Infect Dis 2012;16:e597-e602.
13. Shindoh J, Hasegawa K, Matsuyama Y, Inoue Y, Ishizawa T, Aoki T, et al. Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus. J Clin Oncol 2013;31:766-773.
14. Craxì A, Cammà C. Treating patients with HCV genotype 1 and low viraemia: more than meets the eye. J Hepatol 2006;44:4-7.
15. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006;43:954-960.
16. Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008;47:43-50.
17. Ferenci P, Laferl H, Scherzer T-M, Gschwantler M, Maieron A, Brunner H, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008;135:451-458.
18. Sarrazin C, Shiffman ML, Hadziyannis SJ, Lin A, Colucci G, Ishida H, et al. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol 2010;52:832-838.
19. Arase Y, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Kawamura Y, et al. Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load. Intern Med 2009;48:253-258.
20. Craxi A, Koutsounas S, Ogurtsov P, Chemello L, Maticic M, Torras J, et al. Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response. J Viral Hepat 2012;19:e120-e125.
21. Yu M-L, Dai C-Y, Huang J-F, Chiu C-F, Yang Y-HC, Hou N-J, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008;47:1884-1893.
22. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-1217.
23. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.
24. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
25. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-2428.
26. Pearlman BL. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis 2012;12:717-728.
27. Victrelis [package insert] [Internet]. Merck: Whitehouse Station, NJ; 2011. Available from: http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf.
28. Incivek [package insert] [Internet]. Vertex Pharmaceuticals: Cambridge, MA; 2012. Available from: http://pi.vrtx.com/files/uspi_telaprevir.pdf.
29. Gellad ZF, Reed SD, Muir AJ. Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C. Antivir Ther (Lond) 2012;17(6 Pt B):1189-1199.
30. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
31. Marcellin P, Cheinquer H, Curescu M, Dusheiko GM, Ferenci P, Horban A, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012;56:2039-2050.
32. Beinhardt S, Rutter K, Stättermayer AF, Ferenci P. Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus. Clin Infect Dis 2013;56:118-122.
33. Pellicelli AM, Romano M, Stroffolini T, Mazzoni E, Mecenate F, Monarca R, et al. HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b. BMC Gastroenterol 2012;12:162.
34. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-1444.
35. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801.
36. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139:120-129 e18.
37. Jacobson IM, Catlett I, Marcellin P, Bzowej NH, Muir AJ, Adda N, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. EASL, International Liver Congress, Amsterdam, The Netherlands; 2013 (cited 2013 May 1). Available from: http://www1.easl.eu/easl2011/program/Posters/Abstract7.htm.
38. Camma C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012;56:850-860.